Biomind Lab News Today

Biomind Labs Inc. ; class=js-l-obf link link--blue

TORONTO--(BUSINESS WIRE)--Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal...

Biomind Labs and Queen’s University of Belfast Receive Controlled Substances License to Commence the Production of a Novel Transdermal Drug Delivery System - read this article along with other careers information, tips and advice on BioSpace

Biomind Labs Doses First Subject in Phase I/IIa Clinical Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression - read this article along with other careers information, tips and advice on BioSpace

Biomind Labs Inc. ("Biomind Labs" or the "Company") (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company developing the next generation of pharmaceuticals to treat patients suffering from

TORONTO--(BUSINESS WIRE)--Mar 17, 2022--

Biomind Labs Announces DTC Eligibility in the United States - read this article along with other careers information, tips and advice on BioSpace

TORONTO — Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) ( NEO: BMND ) (FSE: 3XI), a leading biotech company in fast-acting psychedelics is…

Press release content from Business Wire. The AP news staff was not involved in its creation.